LLY

1,001.71

+1.15%↑

JNJ

228.39

+1.37%↑

ABBV

206.3

-0.96%↓

UNH

398.54

+2.15%↑

AZN

185.57

+0.3%↑

LLY

1,001.71

+1.15%↑

JNJ

228.39

+1.37%↑

ABBV

206.3

-0.96%↓

UNH

398.54

+2.15%↑

AZN

185.57

+0.3%↑

LLY

1,001.71

+1.15%↑

JNJ

228.39

+1.37%↑

ABBV

206.3

-0.96%↓

UNH

398.54

+2.15%↑

AZN

185.57

+0.3%↑

LLY

1,001.71

+1.15%↑

JNJ

228.39

+1.37%↑

ABBV

206.3

-0.96%↓

UNH

398.54

+2.15%↑

AZN

185.57

+0.3%↑

LLY

1,001.71

+1.15%↑

JNJ

228.39

+1.37%↑

ABBV

206.3

-0.96%↓

UNH

398.54

+2.15%↑

AZN

185.57

+0.3%↑

Home・Aandelen Lijst・Schrodinger Inc

Schrodinger Inc

Open

SectorGezondheidszorg

12.65 0.16

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.52

Max

12.85

Belangrijke statistieken
By Trading Economics
Inkomsten	-196M -60M
Verkoop	-29M 59M
EPS	-0.621
Winstmarge	-102.456
Werknemers	850
EBITDA	-85M -49M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+51.34% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-13M 950M
Vorige openingsprijs	12.49
Vorige sluitingsprijs	12.65

Nieuwssentiment

By Acuity

50%

150 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

23.27 / 26.13 Steun & Weerstand

Schrodinger Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mei 2026, 22:50 UTC

Winsten

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mei 2026, 22:49 UTC

Winsten

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mei 2026, 22:32 UTC

Winsten

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mei 2026, 23:48 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mei 2026, 22:57 UTC

Marktinformatie

Winsten

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mei 2026, 22:26 UTC

Winsten

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mei 2026, 22:24 UTC

Winsten

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mei 2026, 22:19 UTC

Winsten

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mei 2026, 22:14 UTC

Winsten

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mei 2026, 22:14 UTC

Winsten

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mei 2026, 22:13 UTC

Winsten

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mei 2026, 22:12 UTC

Winsten

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mei 2026, 22:12 UTC

Winsten

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mei 2026, 22:11 UTC

Winsten

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mei 2026, 22:11 UTC

Winsten

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mei 2026, 22:10 UTC

Winsten

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mei 2026, 22:09 UTC

Winsten

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mei 2026, 22:09 UTC

Winsten

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mei 2026, 22:08 UTC

Winsten

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mei 2026, 22:07 UTC

Winsten

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mei 2026, 22:06 UTC

Winsten

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mei 2026, 22:06 UTC

Winsten

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mei 2026, 22:05 UTC

Winsten

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer Vergelijking

Prijswijziging

Schrodinger Inc Prognose

Koersdoel

By TipRanks

51.34% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 19.25 USD 51.34%

Hoogste 24 USD

Laagste 13 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Schrodinger Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Schrodinger Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

23.27 / 26.13Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

150 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.